康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02162 康诺亚-B

未开盘 04-14 16:08:20

74.100

-0.200

-0.27%

最高75.750	最低72.850	成交量240.24万
今开74.350	昨收74.300	日振幅3.90%
总市值221.56亿	流通市值221.56亿	总股本2.99亿
成交额1.78亿	换手率0.80%	流通股本2.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"康诺亚-B","latestPrice":74.1,"timestamp":1776154100005,"preClose":74.3,"halted":0,"volume":2402414,"delay":0,"changeRate":-0.002691790040376889,"floatShares":299000000,"shares":299000000,"eps":-2.19694287773391,"marketStatus":"未开盘","change":-0.2,"latestTime":"04-14 16:08:20","open":74.35,"high":75.75,"low":72.85,"amount":177992876,"amplitude":0.039031,"askPrice":74.4,"askSize":2000,"bidPrice":74.1,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-2.2279991383092064,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776216600000},"marketStatusCode":0,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":74.3,"openAndCloseTimeList":[[1776130200000,1776139200000],[1776142800000,1776153600000]],"volumeRatio":0.6673548329932972,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162","defaultTab":"news","newsList":[{"id":"2624157336","title":"港股异动 | 康诺亚-B(02162)再涨近6% 司普奇拜单抗去年销售快速放量 全球价值兑现路径明晰","url":"https://stock-news.laohu8.com/highlight/detail?id=2624157336","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624157336?lang=zh_cn&edition=full","pubTime":"2026-04-02 14:25","pubTimestamp":1775111117,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康诺亚-B再涨近6%，截至发稿，涨5.97%，报71港元，成交额4.15亿港元。消息面上，康诺亚2025年业绩显示，公司全年实现收入达7.2亿元，其中，康悦达销售收入约3.15亿元，合作收入为4.02亿元。同时公司全球价值兑现路径进一步明晰。开源证券指出，康诺亚凭借大单品司普奇拜单抗销售快速放量，以及对外授权产品首付款确认收入，公司营收端实现快速增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","02162","BK1161","BK4585","VXUS","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624157850","title":"BD+业绩双重炸裂，创新药多股涨停，黄金窗口期来了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2624157850","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624157850?lang=zh_cn&edition=full","pubTime":"2026-04-02 14:03","pubTimestamp":1775109822,"startTime":"0","endTime":"0","summary":"进入收获期","market":"sh","thumbnail":"https://img3.gelonghui.com/a401d-e32ea773-2592-402d-a56d-8ff49dc1dd78.jpg?guru_height=718&guru_width=1280&guru_size=112216","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a401d-e32ea773-2592-402d-a56d-8ff49dc1dd78.jpg?guru_height=718&guru_width=1280&guru_size=112216"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4283048","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["GLDM","GDXY","159831","NUGT","GDX","DZZ","MGCmain","PALL","JDST","PHYS","BK4585","CEF","OUNZ","600488","000788","159934","UGL","GDXJ","GLD","GLL","IAU","600594","GDXU","159992","SGUmain","IAUM","JNUG","SGOL","QOmain","DUST","BK0188","DGP","000950","IAUI","SGCmain","XME","BK1191","GCmain","AAAU","GDXD","1OZmain","518880","02186","GLTR","02162","603222","BTGD","06978","300086","USG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116239395","title":"异动解读 | 受BD交易额超预期及GLP-1药物获批催化，康诺亚-B盘中大涨7.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116239395","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116239395?lang=zh_cn&edition=full","pubTime":"2026-04-02 10:57","pubTimestamp":1775098635,"startTime":"0","endTime":"0","summary":"康诺亚-B今日盘中大涨7.46%，引起了市场的广泛关注。消息面上，行业利好频传。一方面，数据显示2026年前三个月，我国创新药对外授权（BD）交易总额已超过600亿美元，接近去年全年总额的一半，这一超预期的数据提振了市场对整个生物医药板块的信心。另一方面，美国食品药品监督管理局（FDA）批准了礼来公司的GLP-1口服药物上市，此举增强了市场对重磅药物市场前景的乐观预期。在上述行业积极信号的催化下，港股生物医药板块表现活跃，康诺亚-B作为其中一员，股价随之显著拉升。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129917241","title":"康诺亚-B3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1129917241","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129917241?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:45","pubTimestamp":1775033155,"startTime":"0","endTime":"0","summary":"康诺亚生物医药科技有限公司（下称“康诺亚-B”，股票代码：02162）于2026年4月1日披露2026年3月股份变动月报表。公告显示，截至2026年3月31日，公司注册股本维持在500,000,000股（每股面值0.0001美元），相当于总额50,000美元，较上月无任何增减变动。\n公司已发行股份数为298,735,566股，与上月底保持一致。报告期间内，公司未进行任何新增发行、购回或注销股份，也无库存股变动。此外，公司在期权与激励计划方面并无变化。\n截至本月末，公司股本总数保持稳定。公司声明已遵守香港联交所《上市规则》及相关法律规定。该公告由执行董事Bo CHEN博士签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624833564","title":"创新药概念股强势走高 乐普生物-B(02157)涨14.79% 机构指板块迎来多重共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2624833564","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624833564?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:19","pubTimestamp":1775020740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股强势走高，乐普生物-B 涨14.79%，荣昌生物涨14.41%，欧康维视生物-B涨14.25%，亚盛医药-B涨12.07%，博安生物涨11.41%，诺诚健华涨11.21%，海西新药涨11.19%，三生制药涨10.78%，康诺亚-B涨10.21%。华鑫证券表示，2026年中国创新出海趋势持续强化，同时市场对创新药配置有望回升，维持医药行业“推荐”的评级。创新药迎来重要配置机遇，看好目前处于领先位置的双抗和多抗组合。期待今年年4-6月重磅学术会议带来的中国创新药企重磅研究。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978033","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","02157","BK1574","BK1161","02637","BK1587","BK1583","BK1593","01530","01477","02162","159992","09969","06955","BK1191","06978","09995","HK0000165453.HKD","LU1969619763.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156667850","title":"异动解读 | 年度收入大增67.3%，康诺亚-B盘中大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156667850","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156667850?lang=zh_cn&edition=full","pubTime":"2026-03-27 14:00","pubTimestamp":1774591208,"startTime":"0","endTime":"0","summary":"康诺亚-B(02162)今日盘中股价大幅上涨5.12%，引起了市场关注。消息面上，公司公布了2025年度业绩报告。数据显示，公司全年收入录得7.16亿元人民币，按年大幅增长67.3%，显示出强劲的业务扩张势头。尽管年度亏损由上年的5.15亿元略扩至5.23亿元，且公司不派发末期股息，但市场似乎更聚焦于其营收的高速增长。对于生物科技类公司而言，营收的快速增长往往被视为衡量其产品商业化能力和未来潜力的关键指标。此次业绩中收入的大幅提升，可能增强了投资者对公司发展前景的信心，从而推动了股价在交易时段的上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622868626","title":"康诺亚-B(02162)发布年度业绩 股东应占亏损5.23亿元 同比扩大1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622868626","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622868626?lang=zh_cn&edition=full","pubTime":"2026-03-26 20:58","pubTimestamp":1774529912,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B(02162)发布截至2025年12月31日止年度业绩，该集团期内取得收入7.16亿元人民币，同比增加67%;母公司拥有人应占亏损5.23亿元，同比扩大1.44%;每股基本亏损1.91元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02162","BK1583","BK1574","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112843274","title":"港股生物医药板块涨幅居前，康方生物涨超5%，科伦博泰生物涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112843274","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112843274?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:54","pubTimestamp":1774490076,"startTime":"0","endTime":"0","summary":"3月26日，$生物(000504)$医药板块涨幅居前，$康方生物(09926)$涨超5%，$科伦博泰(06990)$生物涨超4%，$泰格医药(03347)$、$荣昌生物(09995)$涨超3%，$药明康德(02359)$、$君实生物(01877)$等个股跟涨","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0a8a9829d43b93c325f4de1fe2adcf40","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU0348767384.USD","BK4588","LU1794554557.SGD","LU0348827113.USD","03347","BK4585","LU0348825331.USD","LU0417516738.SGD","LU2476274308.USD","IE00BPRC5H50.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK1161","LU0634319403.HKD","LU0417516902.SGD","LU1720050803.USD","BK4581","LU2778985437.USD","01877","LU2399975544.HKD","LU0348783233.USD","LU0417516571.SGD","09926","LU0540923850.HKD","BK1574","LU0348784397.USD","09995","02162","LU0348766576.USD","LU0561508036.HKD","LU1961090484.USD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621068652","title":"超21亿美元抢滩TCE，吉利德收购康诺亚NewCo合作公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068652","media":"21世纪经济报道","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621068652?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:20","pubTimestamp":1774344000,"startTime":"0","endTime":"0","summary":"3月24日，康诺亚（02162.HK）发布公告称，公司NewCo合作企业OuroMedicines已与吉利德科学（简称“吉利德”，NASDQ：GILD）签署并购协议，吉利德将以并购方式收购OuroMedicines。此次交易总金额可达21.75亿美元，包括16.75亿美元首付款（可按惯例调整）和最高5亿美元里程碑付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682648353.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682648353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","02162","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621032441","title":"吉利德拟以最高21.75亿美元收购Ouro Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2621032441","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621032441?lang=zh_cn&edition=full","pubTime":"2026-03-24 11:18","pubTimestamp":1774322333,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1574","02162","BK1161","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621038311","title":"康诺亚-B(02162)：持股公司Ouro Medicines被吉利德收购 预计获最高约3.2亿美元收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2621038311","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621038311?lang=zh_cn&edition=full","pubTime":"2026-03-24 06:47","pubTimestamp":1774306066,"startTime":"0","endTime":"0","summary":"紧随完成后，本集团将不再持有Ouro Medicines的任何股权。截至2025年12月31日，本集团自其于Ouro Medicines的股权录得未变现公允价值收益100万美元。董事认为，并购协议乃由买方与Ouro Medicines按公平原则磋商达成，按正常商业条款订立，属公平合理，而并购协议条款及其项下拟进行的交易符合本公司及其股东的整体利益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417737.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康诺亚-B(02162)：持股公司Ouro Medicines被吉利德收购 预计获最高约3.2亿美元收益","news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1587","02162","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154663615","title":"康诺亚-B(Keymed)拟向吉利德出售Ouro Medicines全部15%股权 最高获3.2 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154663615","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154663615?lang=zh_cn&edition=full","pubTime":"2026-03-24 06:35","pubTimestamp":1774305343,"startTime":"0","endTime":"0","summary":"康诺亚-B24日在港交所发布公告称，其全资子公司一桥香港持有的Ouro Medicines约15%股权将于2026年3月23日以并购方式转让给吉利德科学公司。交易完成后，康诺亚-B不再持有Ouro Medicines任何权益。里程碑付款最高5 亿美元；总对价上限21.75 亿美元。合计最高3.2 亿美元。集团此前在Ouro Medicines股权上已录得未变现公允价值收益100万美元，本次交易的会计处理需待审计确认。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116881285","title":"康诺亚-B并购案预期收益：2.5亿美元首付款及其他收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1116881285","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116881285?lang=zh_cn&edition=full","pubTime":"2026-03-24 06:33","pubTimestamp":1774305194,"startTime":"0","endTime":"0","summary":"康诺亚生物医药（KeyMed Biosciences）近期披露的并购交易细节显示，该集团有望从此次合并中获得显著收益。交易结构包括一笔高达2.5亿美元的首期付款，以及其他潜在财务收益。这一并购安排预计将为集团带来可观的资金流入，进一步增强其财务实力和业务拓展能力。\n市场分析指出，此次并购不仅能够为康诺亚-B提供即时资金支持，还可能为其长期发展注入新的动力。交易的具体条款和后续收益分配机制，将成为投资者关注的焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1583","02162","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620203185","title":"【券商聚焦】中国银河：“十五五”首次将生物医药列为国家新兴支柱产业，持续发力研发创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203185","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620203185?lang=zh_cn&edition=full","pubTime":"2026-03-20 09:23","pubTimestamp":1773969824,"startTime":"0","endTime":"0","summary":"“十四五”规划重点关注医药创新产品产业化、医药产业化技术攻关、疫苗和短缺药品供应保障、产品质量升级、医药工业绿色低碳等五大工程，成效斐然，中国创新药获批上市数量由2015年的11款提升至2024年的92款，2024年共有22款国产化药和17款国产生物药获批上市，国产创新药占比提升至42%。“十五五”规划提出健全医疗、医保、医药协同发展和治理机制，生物医药产业首次被列为国家“新兴支柱产业”，战略定位进一步提升。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976888","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK0276","BK1564","BK4588","LU2045819591.USD","02268","BK4581","LU0348767384.USD","LU0561508036.HKD","LU0708995583.HKD","LU1720050803.USD","XBI","02359","LU2125910500.SGD","BK4585","LU2476274308.USD","LU0348825331.USD","LU2778985437.USD","02696","HK0000320223.HKD","SG9999014674.SGD","HK0000306685.HKD","09926","LU0052750758.USD","02162","06881","LU0348735423.USD","LU1969619763.USD","399441","LU0417516571.SGD","LU0196878994.USD","BK1588","BK1161","IE00B543WZ88.USD","LU2328871848.SGD","09995","161726","06160","BK1147","HK0000306701.USD","BK1141","LU1770034418.SGD","LU0540923850.HKD","LU2476274720.SGD","601881","LU0348766576.USD","LU2242644610.SGD","LU0307460666.USD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618791903","title":"港股异动 | 康诺亚-B(02162)再涨超3% CMG901获阿斯利康4500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2618791903","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618791903?lang=zh_cn&edition=full","pubTime":"2026-03-12 09:51","pubTimestamp":1773280266,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康诺亚-B再涨超3%，截至发稿，涨2.21%，报55.5港元，成交额750.96万港元。根据许可协议条款及条件的规限下，上述临床试验完成首例受试者给药已触发相关里程碑付款，总金额为4500万美元。阿斯利康已支付该里程碑款项。公开资料显示，康诺亚和乐普生物合资设立的KYM Biosciences Inc.于2023年2年与阿斯利康订立全球独家许可协议，授权阿斯利康在全球范围开发及商业化CMG901。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","BK4568","LU0058720904.USD","BK4588","02162","LU0109394709.USD","LU0889565916.HKD","LU2456880835.USD","BK1583","BK4007","LU2417539215.USD","IE00B3T34201.USD","LU2236285917.USD","LU2462157665.USD","LU0320765992.SGD","LU0289739699.SGD","LU1829250122.USD","VXUS","BK1574","AZN","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618792904","title":"每日卖空追踪 | 康诺亚-B 03月11日卖空量成交11.3万股，卖空比例为15.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618792904","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618792904?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217828,"startTime":"0","endTime":"0","summary":"康诺亚-B北京时间03月11日，跌0.73%，卖空量成交11.3万股，较上一交易日减少62.46%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163351a460b683&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163351a460b683&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","BK1587","BK1583","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618974387","title":"康诺亚-B03月11日遭主力抛售261.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618974387","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618974387?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:15","pubTimestamp":1773216953,"startTime":"0","endTime":"0","summary":"03月11日, 康诺亚-B股价跌0.73%，报收54.30元，成交金额4030.9万元，换手率0.25%，振幅4.20%，量比0.34。康诺亚-B今日主力资金净流出261.9万元，连续3日净流出，上一交易日主力净流出655.1万元。该股近5个交易日上涨17.82%，主力资金累计净流出1018.6万元；近20日主力资金累计净流出912.7万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162019a460ab28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162019a460ab28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02162","BK1574","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618290419","title":"中国KYM Biosciences：收到4500万美金MNC药企付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2618290419","media":"药融圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618290419?lang=zh_cn&edition=full","pubTime":"2026-03-11 13:15","pubTimestamp":1773206151,"startTime":"0","endTime":"0","summary":"药融圈监测显示：中国药企KYM Biosciences Inc.于2023年2年与 阿斯利康 AstraZeneca订立全球独家许可协议，授权AstraZeneca在全球范围开发及商业化CMG901。基于当时的许可协议，KYM将获得6300万美元预付款和超过11亿美元的潜在额外开发和销售相关里程碑付款。目前，AstraZeneca已就AZD0901治疗晚期实体瘤开展了多项全球临床研究，适应症含括胃癌、胰腺癌及胆道癌等等。近期在2026年3月10日，根据许可协议条款及条件，临床研究进展触发总金额4500万美元里程碑付款，已经到账。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311133823a4604bcf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311133823a4604bcf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1574","BK1161","02162","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618993297","title":"康诺亚收到4500万美元里程碑付款；辉瑞全球首创三抗II期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2618993297","media":"氨基观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618993297?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:40","pubTimestamp":1773142800,"startTime":"0","endTime":"0","summary":"根据许可协议条款及条件，该研究进展触发总金额4500万美元里程碑付款。辉瑞全球首创三抗II期研究成功。/ 01 /市场速递1）康诺亚收到4500万美元里程碑付款3月10日，康诺亚宣布，公司核心产品Claudin18.2 ADC CMG901在全球授权合作伙伴阿斯利康推动下，已启动一项III期临床研究，并完成了首例受试者给药。2）辉瑞全球首创三抗II期研究成功3月9日，辉瑞宣布，在研IL-4/IL-13/TSLP三特异性抗体Tilrekimig治疗中重度特应性皮炎的II期研究取得了积极结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310203649a45ea18a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310203649a45ea18a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02162","BK1161","BK1574","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618939295","title":"康诺亚CMG901获阿斯利康4500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939295","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618939295?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:18","pubTimestamp":1773137907,"startTime":"0","endTime":"0","summary":"北京商报讯3月10日，康诺亚发布公告，更新了与AstraZeneca（阿斯利康）就核心产品CMG901（AZD0901）合作的最新情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667582417.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667582417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0109394709.USD","BK4568","LU0289739699.SGD","BK4588","LU2456880835.USD","LU2417539215.USD","BK4585","IE00B3T34201.USD","BK4007","BK1587","BK1161","LU0889565916.HKD","LU2236285917.USD","LU0058720904.USD","LU2462157665.USD","LU0320765992.SGD","AZN","BK1583","BK1574","LU1829250122.USD","02162"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0385},{"period":"1month","weight":0.4087},{"period":"3month","weight":0.2475},{"period":"6month","weight":0.1185},{"period":"1year","weight":0.6358},{"period":"ytd","weight":0.3863}],"compareEarnings":[{"period":"1week","weight":0.0301},{"period":"1month","weight":0.016},{"period":"3month","weight":-0.0418},{"period":"6month","weight":-0.0006},{"period":"1year","weight":0.208},{"period":"ytd","weight":0.0094}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康诺亚生物医药科技有限公司是一家生物科技公司，专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法的公司。该公司还专注于医药产品的研究和开发。该公司的主要产品有CM310、CM326、CM313和CM383，可治疗各种成人、青少年及儿童I型免疫性疾病，例如中重度特应性皮炎、中重度哮喘、慢性鼻賨炎伴鼻息肉、过敏性鼻炎，亦可能可以治疗慢性阻塞性肺疾病。该公司还建立了涵盖生物药开发的关键功能的全面一体化平台。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.062159},{"month":2,"riseRate":0.6,"avgChangeRate":0.057033},{"month":3,"riseRate":0.4,"avgChangeRate":0.01927},{"month":4,"riseRate":1,"avgChangeRate":0.074485},{"month":5,"riseRate":0.25,"avgChangeRate":-0.097555},{"month":6,"riseRate":1,"avgChangeRate":0.124436},{"month":7,"riseRate":0.5,"avgChangeRate":0.132155},{"month":8,"riseRate":0.6,"avgChangeRate":0.038036},{"month":9,"riseRate":0.8,"avgChangeRate":0.042936},{"month":10,"riseRate":0.4,"avgChangeRate":0.003137},{"month":11,"riseRate":0.6,"avgChangeRate":0.04569},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144855}],"exchange":"SEHK","name":"康诺亚-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康诺亚-B,02162,康诺亚-B股票,康诺亚-B股票老虎,康诺亚-B股票老虎国际,康诺亚-B行情,康诺亚-B股票行情,康诺亚-B股价,康诺亚-B股市,康诺亚-B股票价格,康诺亚-B股票交易,康诺亚-B股票购买,康诺亚-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}